ABCG2 x chloride channel x SRPK1 x UGT1A1 - 药物、适应症、专利

An?open-label phase II prospective clinical trial to?investigate safety, tolerability, maximum tolerated dose and anti-tumor?effect for SCO-101 in combination with?FOLFIRI?as?a safe and efficient treatment modality?in metastatic or advanced colorectal cancer (mCRC) patients with acquired?FOLFIRI?resistant cancer disease.

开始日期2022-01-17

申办/合作机构

Scandion Oncology A/S

NCT04652206

/ Unknown status临床1/2期

An Open-label Phase Ib Prospective Clinical Trial to Investigate Safety, Tolerability and Maximum Tolerated Dose for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.

An open-label dose escalating phase Ib study of SCO-101 in combination with gemcitabine and nab-paclitaxel. The primary objectives are to establish the safety profile and the MTD of SCO-101 when combined with gemcitabine and nab-paclitaxel. The starting dose of SCO-101 is 150 mg and the dose may be increased to a maximum of 350 mg.

开始日期2020-10-27

申办/合作机构

Scandion Oncology A/S

[+1]

100 项与 ABCG2 x chloride channel x SRPK1 x UGT1A1 相关的临床结果

登录后查看更多信息

100 项与 ABCG2 x chloride channel x SRPK1 x UGT1A1 相关的转化医学

登录后查看更多信息

0 项与 ABCG2 x chloride channel x SRPK1 x UGT1A1 相关的专利（医药）

登录后查看更多信息

分析

对领域进行一次全面的分析。

登录

或

查看完整样例数据